List of Lexiscan drug patents

Lexiscan is owned by Astellas.

Lexiscan contains Regadenoson.

Lexiscan has a total of 3 drug patents out of which 1 drug patent has expired.

Expired drug patents of Lexiscan are:

  • US6403567

Lexiscan was authorised for market use on 10 April, 2008.

Lexiscan is available in solution;intravenous dosage forms.

Lexiscan can be used as method for stimulating coronary vasodilation for purposes of imaging the heart.

The generics of Lexiscan are possible to be released after 02 February, 2027.

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US6403567 ASTELLAS N-pyrazole A2A adenosine receptor agonists
Apr, 2022

(9 months ago)

US8106183 ASTELLAS Process for preparing an A2A-adenosine receptor agonist and its polymorphs
Feb, 2027

(4 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
USRE47301 ASTELLAS Process for preparing an A2A-adenosine receptor agonist and its polymorphs
Feb, 2027

(4 years from now)

Drugs and Companies using REGADENOSON ingredient

Market Authorisation Date: 10 April, 2008

Treatment: Method for stimulating coronary vasodilation for purposes of imaging the heart

Dosage: SOLUTION;INTRAVENOUS

How can I launch a generic of LEXISCAN before it's patent expiration?
More Information on Dosage

availability in other generic markets.

Click on the highlighted region to filter.

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic

Other things you might be interested in